Developer docs
API playgroundTry for free, no card

Search company profiles

Vaniam Group

Full company profile

uuid0005kks

Namestring
Vaniam Group
Legal namestring
Vaniam Group LLC
Websiteurl
vaniamgroup.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Vaniam Group is a privately held, woman-owned oncology organization founded in 2007 that provides consulting, scientific communication, expert engagement, and insights-gathering services to biopharmaceutical companies. The firm operates as a platform-plus-modules architecture, with three core operating subsidiaries: Bio Ascend (medical education for oncology, hematology, cell therapy, rare disease, and immunology), Curio Science (subscription intelligence platform connecting a network of 14,000+ HCPs and patients), and Women Leaders in Oncology (community organization and Young Investigator Awards program). It is staffed by 251-500 specialists distributed across the United States in a fully virtual operating model registered at a single Chicago headquarters.

The firm's central technology is Vaniam Intelligence, a proprietary AI platform launched in May 2025 and built exclusively on twenty years of longitudinal oncology engagement data accumulated through Curio Science. The platform supports predictive analytics (including the Predictive Pathways module for forecasting market shifts 60-90 days ahead), knowledge retrieval, generative insights, and workflow automation for biopharma medical affairs and commercial teams. The data asset is engagement-derived rather than assembled from external sources, and the platform is positioned as purpose-built rather than adapted from general-purpose technology.

Vaniam Group generates revenue through four streams: project-based medical communications services (publications, advisory boards, congress programming, MSL resources, KOL engagement); Curio Science subscriptions providing longitudinal HCP and patient insights; Bio Ascend medical education programs developed with accredited CME providers; and Vaniam Intelligence enterprise licensing. Pricing is not publicly disclosed and is quote-based for custom solutions. The go-to-market is enterprise field sales targeted at biopharma medical affairs and commercial teams, supplemented by subscription inside-sales for Curio Science and an event-driven presence at major oncology congresses, particularly ASCO. The firm is WBENC-certified, holds an EcoVadis Platinum sustainability rating (top 1% globally), and has appeared on the Inc. 5000 list across multiple consecutive years.

Short descriptiontext

Vaniam Group is a privately held, woman-owned oncology organization providing scientific communications, medical education, and AI-powered intelligence services to biopharmaceutical companies. It operates Bio Ascend (education), Curio Science (14,000+ HCP subscription platform), and Vaniam Intelligence (proprietary AI for oncology strategy).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology medical communications, biopharma intelligence platform, healthcare provider insights, patient engagement services, oncology medical education
Industry2 codes
PRIMARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Health Services8000
Product category
Oncology Medical Communications & Biopharma Intelligence
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Medical Communications Services
TypeProfessional Services
Description

Full-service medical communications including publications, scientific platforms, advisory boards, congress programming, MSL resources, scientific exchange, and thought leader engagement. Revenue derived from project-based engagements with biopharma medical affairs and commercial teams.

vaniamgroup.com
2Curio Science Subscription
TypeSubscription Recurring
Description

Subscription-based oncology intelligence platform providing longitudinal insights from a network of 14,000+ HCPs. Biopharma clients subscribe for access to curated insights, analytics, and strategic intelligence.

vaniamgroup.com
3Bio Ascend Medical Education
TypeProfessional Services
Description

Medical education programs including CME activities developed in partnership with accredited providers and non-CME scientific education programs. Revenue from biopharma medical affairs teams, foundations, and academic institutions.

vaniamgroup.com
4Vaniam Intelligence Platform Access
TypeSubscription Recurring
Description

Access to AI-powered analytics platform with configurable, scalable insights for biopharma strategic decision-making. Platform features including Predictive Pathways are delivered through enterprise licensing arrangements.

vaniamgroup.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Vaniam Intelligence™
Description

Purpose-built AI platform integrating proprietary artificial intelligence with human expertise to transform biopharma strategy and decision-making.

vaniamgroup.com
+5 more records
Core offering1 text field

Vaniam Group delivers oncology-focused medical communications, medical education, patient engagement, and AI-powered intelligence services to biopharma companies. Its offerings include scientific platforms, publications, advisory boards, congress programming, KOL engagement, MSL resources, and a proprietary AI platform (Vaniam Intelligence) built on 20 years of longitudinal insight from a 14,000+ HCP network. The company also operates Curio Science (subscription HCP/patient intelligence), Bio Ascend (medical education), and Vaniam Patient Network.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 14,000+ HCPs in Curio Science network generating longitudinal oncology insights
+2 more records
Product overview1 text field

Vaniam Group is an integrated oncology organization operating as a platform-plus-modules architecture. The core platform is Vaniam Intelligence, a proprietary AI system powered by longitudinal oncology insight from 20 years of engagement. This platform is enhanced by Predictive Pathways, a forecasting capability. Vaniam Group's portfolio includes Curio Science (HCP/patient subscription intelligence with 14,000+ HCP network), Bio Ascend (medical education), Women Leaders in Oncology (community/awards), Patient Engagement services, and Vaniam Patient Network. These components work together: Curio Science generates the proprietary data that feeds Vaniam Intelligence, which then delivers actionable insights across the organization's medical communications and patient engagement services.

Product and service7 records
1Vaniam Intelligence
CategoryAI Platform / Biopharma Intelligence
Description

Purpose-built AI platform powered by proprietary longitudinal oncology insight that integrates data, strategic insights, and advanced analytics to help biopharma teams make confident decisions from clinical development to commercialization.

2Curio Science
CategorySubscription Intelligence Platform
Description

Subscription intelligence platform connecting HCPs and patients through scientifically rigorous engagement to generate longitudinal oncology insights, with a network of 14,000+ HCPs.

3Bio Ascend Medical Education
CategoryMedical Education
Description

Medical education company specializing in oncology, hematology, cell therapy, rare disease, metabolic disorders, and immunology. Designs scientific education for clinicians at conferences and academic settings, including CME and non-CME programs developed with accredited providers and biopharma medical affairs teams.

4Patient Engagement Services
CategoryPatient Engagement Services
Description

Partnership with patients and caregivers to shape drug development from earliest stages through commercialization, including patient insights, content co-creation, digital engagement, and advocacy programs.

5Vaniam Patient Network
CategoryPatient Network / Patient Engagement
Description

Network connecting individuals living with or caring for someone with health challenges to drive innovation in patient care and treatment development, with compensation for engagement; covers breast, lung, prostate, colorectal, pancreatic, ovarian cancers, hematologic malignancies, and rare diseases.

6Medical Communications
CategoryMedical Communications Services
Description

Full spectrum of scientific communications, medical affairs support, and creative execution including strategy, narrative, publications, congress programming, advisory boards, KOL engagement, scientific platforms, and MSL resources for biopharma clients.

7Customizable Intelligence Solutions
CategoryIntelligence / Consulting Services
Description

AI-enabled framework providing configurable, scalable intelligence solutions designed to turn oncology insight into actionable clarity for biopharma teams.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-04
Description

Strategic transition in which Bio Ascend, Vaniam Group's medical education company, assumes stewardship of the International Workshop on NHL (iwNHL) and International Workshop on Multiple Myeloma (iwMyeloma). These are leading forums in hematologic oncology. Dr. Stuart W. G. Smith will continue collaborating with the new leadership to guide continued evolution and global expansion. Bio Ascend takes primary responsibility for organization, delivery, and future development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-30
Description

Partnership to present Young Investigator Awards at ASCO Annual Meeting. Vaniam Group and Women Leaders in Oncology fund awards through Conquer Cancer, the ASCO Foundation. Awards support early-career physician-scientists advancing oncology research. Vaniam Group CEO Deanna B. van Gestel serves as Board Member of Conquer Cancer.

3Academy of Next Wave of Investigators
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-10
Description

Bio Ascend-led program convening young clinical investigators for year-long mentorship through professional development led by international thought leaders. Faculty includes renowned oncologists from Johns Hopkins, Emory University, MD Anderson, Memorial Sloan Kettering, and other leading institutions. 18 investigators selected for 2024-2025 class in thoracic oncology.

vaniamgroup.com
4Accredited CME Providers
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bio Ascend develops accredited educational activities in partnership with accredited CME providers—academic medical centers and independent accredited education companies. Programs are designed, delivered, and evaluated in accordance with standards of accrediting partners.

vaniamgroup.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnerships with patient advocacy organizations to build and facilitate ambassador and mentor programs, strengthen networks, elevate community voices, and ensure strategies are rooted in lived experiences.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialized life sciences consulting firm focused on commercial strategy, analytics, and forecasting for biopharma; comparable in target customers and data-driven decision support.

TypeDirect peer
Description

Global health and wellness communications and advisory platform serving biopharma with medical communications, transformation, and patient engagement services; comparable as a scaled oncology-adjacent peer.

TypeDirect peer
Description

Data-driven healthcare communications and marketing agency combining proprietary data, AI, and creative services for biopharma clients; directly comparable in blending scientific communications with proprietary intelligence and AI tooling.

TypeDirect peer
Description

Global medical communications and biopharma services group that explicitly acquired Cherie Myatt's former CM Group, making it the closest direct peer to Vaniam Group in oncology-focused medical communications, patient engagement, and strategic consulting.

TypeBroad incumbent
Description

Global healthcare communications network serving biopharma, payers, and providers with creative, medical, and data capabilities; competes with Vaniam on enterprise oncology medical communications engagements.

TypeDirect peer
Description

Biopharma strategic intelligence and consulting firm offering primary market research, advanced analytics, and commercial strategy for oncology and rare disease; comparable as a subscription-and-advisory intelligence provider to biopharma.

TypeDirect peer
Description

Specialized biopharma services platform covering medical communications, market access, and commercial strategy with strong oncology presence; comparable in target customers, therapeutic focus, and integrated service model.

TypeDirect peer
Description

Independent life sciences commercialization services company providing medical affairs, patient services, and data-driven commercial strategy for biopharma; comparable in oncology and rare disease focus with bundled service offerings.

TypeBroad incumbent
Description

Largest healthcare communications holding company with multiple agencies serving biopharma in oncology and other therapeutic areas; broader portfolio and not oncology-specialized but competes for the same enterprise medical affairs and medical communications RFPs.

TypeDirect peer
Description

Global biopharma commercialization and medical communications organization with deep oncology capability; comparable in scientific communications, publications, and KOL engagement offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vaniam Group

Oncology Medical Communications & Biopharma Intelligencevaniamgroup.com

Vaniam Group is a privately held, woman-owned oncology organization providing scientific communications, medical education, and AI-powered intelligence services to biopharmaceutical companies. It operates Bio Ascend (education), Curio Science (14,000+ HCP subscription platform), and Vaniam Intelligence (proprietary AI for oncology strategy).

What Vaniam Group does

Vaniam Group is a privately held, woman-owned oncology organization founded in 2007 that provides consulting, scientific communication, expert engagement, and insights-gathering services to biopharmaceutical companies. The firm operates as a platform-plus-modules architecture, with three core operating subsidiaries: Bio Ascend (medical education for oncology, hematology, cell therapy, rare disease, and immunology), Curio Science (subscription intelligence platform connecting a network of 14,000+ HCPs and patients), and Women Leaders in Oncology (community organization and Young Investigator Awards program). It is staffed by 251-500 specialists distributed across the United States in a fully virtual operating model registered at a single Chicago headquarters.

The firm's central technology is Vaniam Intelligence, a proprietary AI platform launched in May 2025 and built exclusively on twenty years of longitudinal oncology engagement data accumulated through Curio Science. The platform supports predictive analytics (including the Predictive Pathways module for forecasting market shifts 60-90 days ahead), knowledge retrieval, generative insights, and workflow automation for biopharma medical affairs and commercial teams. The data asset is engagement-derived rather than assembled from external sources, and the platform is positioned as purpose-built rather than adapted from general-purpose technology.

Vaniam Group generates revenue through four streams: project-based medical communications services (publications, advisory boards, congress programming, MSL resources, KOL engagement); Curio Science subscriptions providing longitudinal HCP and patient insights; Bio Ascend medical education programs developed with accredited CME providers; and Vaniam Intelligence enterprise licensing. Pricing is not publicly disclosed and is quote-based for custom solutions. The go-to-market is enterprise field sales targeted at biopharma medical affairs and commercial teams, supplemented by subscription inside-sales for Curio Science and an event-driven presence at major oncology congresses, particularly ASCO. The firm is WBENC-certified, holds an EcoVadis Platinum sustainability rating (top 1% globally), and has appeared on the Inc. 5000 list across multiple consecutive years.

Vaniam Group firmographics

Firmographics
Name
Vaniam Group
Legal name
Vaniam Group LLC
Website
https://vaniamgroup.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Vaniam Group is a privately held, woman-owned oncology organization providing scientific communications, medical education, and AI-powered intelligence services to biopharmaceutical companies. It operates Bio Ascend (education), Curio Science (14,000+ HCP subscription platform), and Vaniam Intelligence (proprietary AI for oncology strategy).
Ownership category
akta.pro rank

Vaniam Group industry classification

Industry
Product category
Oncology Medical Communications & Biopharma Intelligence
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Oncology medical communications
  • Biopharma intelligence platform
  • Healthcare provider insights
  • Patient engagement services
  • Oncology medical education

Where Vaniam Group is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vaniam Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D

Revenue model

  1. Medical Communications Services: Full-service medical communications including publications, scientific platforms, advisory boards, congress programming, MSL resources, scientific exchange, and thought leader engagement. Revenue derived from project-based engagements with biopharma medical affairs and commercial teams.
  2. Curio Science Subscription: Subscription-based oncology intelligence platform providing longitudinal insights from a network of 14,000+ HCPs. Biopharma clients subscribe for access to curated insights, analytics, and strategic intelligence.
  3. Bio Ascend Medical Education: Medical education programs including CME activities developed in partnership with accredited providers and non-CME scientific education programs. Revenue from biopharma medical affairs teams, foundations, and academic institutions.
  4. Vaniam Intelligence Platform Access: Access to AI-powered analytics platform with configurable, scalable insights for biopharma strategic decision-making. Platform features including Predictive Pathways are delivered through enterprise licensing arrangements.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Vaniam Group product offering

Product offering

Core offering

Vaniam Group delivers oncology-focused medical communications, medical education, patient engagement, and AI-powered intelligence services to biopharma companies. Its offerings include scientific platforms, publications, advisory boards, congress programming, KOL engagement, MSL resources, and a proprietary AI platform (Vaniam Intelligence) built on 20 years of longitudinal insight from a 14,000+ HCP network. The company also operates Curio Science (subscription HCP/patient intelligence), Bio Ascend (medical education), and Vaniam Patient Network.

Product overview

Vaniam Group is an integrated oncology organization operating as a platform-plus-modules architecture. The core platform is Vaniam Intelligence, a proprietary AI system powered by longitudinal oncology insight from 20 years of engagement. This platform is enhanced by Predictive Pathways, a forecasting capability. Vaniam Group's portfolio includes Curio Science (HCP/patient subscription intelligence with 14,000+ HCP network), Bio Ascend (medical education), Women Leaders in Oncology (community/awards), Patient Engagement services, and Vaniam Patient Network. These components work together: Curio Science generates the proprietary data that feeds Vaniam Intelligence, which then delivers actionable insights across the organization's medical communications and patient engagement services.

Differentiator

Problem solved

Functional benefit

Brands

  • Vaniam Intelligence™: Purpose-built AI platform integrating proprietary artificial intelligence with human expertise to transform biopharma strategy and decision-making.
  • Predictive Pathways
  • Vaniam Patient Network™
  • Women Leaders in Oncology®
  • Bio Ascend™
  • Curio Science

Products and services

  • Vaniam Intelligence Purpose-built AI platform powered by proprietary longitudinal oncology insight that integrates data, strategic insights, and advanced analytics to help biopharma teams make confident decisions from clinical development to commercialization.
  • Curio Science Subscription intelligence platform connecting HCPs and patients through scientifically rigorous engagement to generate longitudinal oncology insights, with a network of 14,000+ HCPs.
  • Bio Ascend Medical Education Medical education company specializing in oncology, hematology, cell therapy, rare disease, metabolic disorders, and immunology. Designs scientific education for clinicians at conferences and academic settings, including CME and non-CME programs developed with accredited providers and biopharma medical affairs teams.
  • Patient Engagement Services Partnership with patients and caregivers to shape drug development from earliest stages through commercialization, including patient insights, content co-creation, digital engagement, and advocacy programs.
  • Vaniam Patient Network Network connecting individuals living with or caring for someone with health challenges to drive innovation in patient care and treatment development, with compensation for engagement; covers breast, lung, prostate, colorectal, pancreatic, ovarian cancers, hematologic malignancies, and rare diseases.
  • Medical Communications Full spectrum of scientific communications, medical affairs support, and creative execution including strategy, narrative, publications, congress programming, advisory boards, KOL engagement, scientific platforms, and MSL resources for biopharma clients.
  • Customizable Intelligence Solutions AI-enabled framework providing configurable, scalable intelligence solutions designed to turn oncology insight into actionable clarity for biopharma teams.

Quantifiable outcome

  • 14,000+ HCPs in Curio Science network generating longitudinal oncology insights
  • +2 more outcomes

Companies that use Vaniam Group

Customer profile

Segments3 records

Ideal customer profiles2 records

Vaniam Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature8 records

Vaniam Group partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • World Health CommunicationscoreStrategic or Co-development Partner · 4 June 2026Strategic transition in which Bio Ascend, Vaniam Group's medical education company, assumes stewardship of the International Workshop on NHL (iwNHL) and International Workshop on Multiple Myeloma (iwMyeloma). These are leading forums in hematologic oncology. Dr. Stuart W. G. Smith will continue collaborating with the new leadership to guide continued evolution and global expansion. Bio Ascend takes primary responsibility for organization, delivery, and future development.
  • Conquer Cancer (ASCO Foundation)coreStrategic or Co-development Partner · 30 May 2025Partnership to present Young Investigator Awards at ASCO Annual Meeting. Vaniam Group and Women Leaders in Oncology fund awards through Conquer Cancer, the ASCO Foundation. Awards support early-career physician-scientists advancing oncology research. Vaniam Group CEO Deanna B. van Gestel serves as Board Member of Conquer Cancer.
  • Academy of Next Wave of InvestigatorscoreStrategic or Co-development Partner · 10 June 2024Bio Ascend-led program convening young clinical investigators for year-long mentorship through professional development led by international thought leaders. Faculty includes renowned oncologists from Johns Hopkins, Emory University, MD Anderson, Memorial Sloan Kettering, and other leading institutions. 18 investigators selected for 2024-2025 class in thoracic oncology.
  • Accredited CME ProviderscoreStrategic or Co-development PartnerBio Ascend develops accredited educational activities in partnership with accredited CME providers—academic medical centers and independent accredited education companies. Programs are designed, delivered, and evaluated in accordance with standards of accrediting partners.
  • Patient Advocacy OrganizationsminorStrategic or Co-development PartnerPartnerships with patient advocacy organizations to build and facilitate ambassador and mentor programs, strengthen networks, elevate community voices, and ensure strategies are rooted in lived experiences.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Vaniam Group competitors and assessment

Company assessment

Direct peers

  • Beghou Consulting: Specialized life sciences consulting firm focused on commercial strategy, analytics, and forecasting for biopharma; comparable in target customers and data-driven decision support.
  • Inizio Evoke: Global health and wellness communications and advisory platform serving biopharma with medical communications, transformation, and patient engagement services; comparable as a scaled oncology-adjacent peer.
  • Real Chemistry: Data-driven healthcare communications and marketing agency combining proprietary data, AI, and creative services for biopharma clients; directly comparable in blending scientific communications with proprietary intelligence and AI tooling.
  • OPEN Health Group: Global medical communications and biopharma services group that explicitly acquired Cherie Myatt's former CM Group, making it the closest direct peer to Vaniam Group in oncology-focused medical communications, patient engagement, and strategic consulting.
  • Trinity Life Sciences: Biopharma strategic intelligence and consulting firm offering primary market research, advanced analytics, and commercial strategy for oncology and rare disease; comparable as a subscription-and-advisory intelligence provider to biopharma.
  • Precision Medicine Group: Specialized biopharma services platform covering medical communications, market access, and commercial strategy with strong oncology presence; comparable in target customers, therapeutic focus, and integrated service model.
  • EVERSANA: Independent life sciences commercialization services company providing medical affairs, patient services, and data-driven commercial strategy for biopharma; comparable in oncology and rare disease focus with bundled service offerings.
  • Fishawack Health (Avalere): Global biopharma commercialization and medical communications organization with deep oncology capability; comparable in scientific communications, publications, and KOL engagement offerings.

Broad incumbents

  • Publicis Health: Global healthcare communications network serving biopharma, payers, and providers with creative, medical, and data capabilities; competes with Vaniam on enterprise oncology medical communications engagements.
  • Omnicom Health Group: Largest healthcare communications holding company with multiple agencies serving biopharma in oncology and other therapeutic areas; broader portfolio and not oncology-specialized but competes for the same enterprise medical affairs and medical communications RFPs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Vaniam Group social profiles

Digital presence

Vaniam Group compliance and trust

Trust signal

Compliance2 records

Vaniam Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vaniam Group leadership team

Management profile

Number of profiles

Profiles11 records

Vaniam Group subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Vaniam Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vaniam Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaniam Group

What does Vaniam Group do?

Vaniam Group delivers oncology-focused medical communications, medical education, patient engagement, and AI-powered intelligence services to biopharma companies. Its offerings include scientific platforms, publications, advisory boards, congress programming, KOL engagement, MSL resources, and a proprietary AI platform (Vaniam Intelligence) built on 20 years of longitudinal insight from a 14,000+ HCP network. The company also operates Curio Science (subscription HCP/patient intelligence), Bio Ascend (medical education), and Vaniam Patient Network.

Is Vaniam Group a public or private company?

Vaniam Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Vaniam Group founded?

Vaniam Group was founded in 2007. It employs 101 to 250 people.

Where is Vaniam Group based?

Vaniam Group is headquartered in Chicago, United States, in the North America region.

How does Vaniam Group make money?

Four revenue lines are on record. Medical Communications Services are the primary driver. The others are curio Science Subscription, bio Ascend Medical Education and vaniam Intelligence Platform Access.

Who are Vaniam Group's main competitors?

Direct peers on record are Beghou Consulting, Inizio Evoke, Real Chemistry, OPEN Health Group, Trinity Life Sciences, Precision Medicine Group, EVERSANA and Fishawack Health (Avalere). Broad incumbents are Publicis Health and Omnicom Health Group.

Does Vaniam Group have an API?

No public API is recorded for Vaniam Group.

What industry is Vaniam Group in?

Vaniam Group's product category is Oncology Medical Communications & Biopharma Intelligence. Its primary akta.pro industry code is HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D), with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournBio Ascend™, a Vaniam Group™ Company, Assumes Stewardship of iwNHL™ and iwMyeloma™ Workshops, Building on the Longstanding Leadership of World Health CommunicationsVaniam Group and World Health Communications announced a strategic transition in which Bio Ascend, Vaniam Group's medical education company, assumes stewardship of the International Workshop on NHL (iwNHL) and International Workshop on Multiple Myeloma (iwMyeloma) workshops, marking a leadership shift from World Health Communications and founder Dr Stuart W. G. Smith. Bio Ascend will take primary responsibility for the organization, delivery, and future development of both internationally recognized hematologic oncology forums. Dr Smith will continue collaborating with the new leadership to guide the continued evolution and global expansion of the workshops.PR NewswireBio Ascend™, a Vaniam Group™ Company, Assumes Stewardship of iwNHL™ and iwMyeloma™ Workshops, Building on the Longstanding Leadership of World Health CommunicationsVaniam Group and World Health Communications announced a strategic transition in which Bio Ascend, Vaniam Group's medical education subsidiary, assumes leadership of the International Workshop on NHL (iwNHL) and International Workshop on Multiple Myeloma (iwMyeloma). The workshops, which are leading forums in hematologic oncology, will be organized and developed under Bio Ascend's stewardship while building on the foundation established by World Health Communications and its founder Dr. Stuart W. G. Smith. Bio Ascend stated it will focus on expanding the global reach of the workshops while preserving their scientific exchange focus.PR NewswireVaniam Group and Women Leaders in Oncology Honor 2026 Young Investigator Award Recipients at ASCOConquer Cancer, the ASCO Foundation, presented the 2026 Young Investigator Awards funded by Vaniam Group and Women Leaders in Oncology at the 2026 ASCO Annual Meeting in Chicago, recognizing two early-career physician-scientists. Dr. Nia Beckley received the Conquer Cancer–Vaniam Group award for her research on spatial profiling of immune evolution in tumors, while Dr. Jordyn Silverstein received the Conquer Cancer–Women Leaders in Oncology award for her work on circulating tumor cells as a noninvasive method for ovarian cancer treatment selection. Women Leaders in Oncology also hosted its annual event alongside the award presentations to convene oncology leaders, researchers, and allies for panel discussion and fundraising.Pulse 2.0Vaniam Group Appoints Cherie Myatt As Interim PresidentVaniam Group appointed Cherie Myatt as Interim President, effective immediately, to provide executive leadership and guide strategic direction. She will continue leading Patient Engagement and Rare Disease capabilities, bringing experience as founder and CEO of CM Group, acquired by OPEN Health. The appointment underscores the company's focus on stability and sustained value creation.PR NewswireVaniam Group Appoints Cherie Myatt as Interim PresidentVaniam Group announced the appointment of Cherie Myatt as Interim President, effective immediately, with responsibility for executive leadership across the organization. Myatt will guide strategic direction, support operational excellence, and ensure continuity as the company advances its growth and oncology intelligence platform integration. She also continues to lead Vaniam Group's Patient Engagement and Rare Disease capabilities, bringing experience as a former founder and CEO of CM Group, which was acquired by OPEN Health.PR NewswireVaniam Group Launches Predictive Pathways: A New Capability for Anticipating Market-Shaping SignalsVaniam Group has launched Predictive Pathways, a new capability within its Vaniam Intelligence platform designed to help biopharma teams anticipate market-shaping shifts 60 to 90 days in advance. The system utilizes evidence-based relational analysis of various data streams to surface early directional shifts and forecast scenarios with explicit confidence levels. This release expands the company's service offerings for clients seeking forward-looking strategic insights.PR NewswireVaniam Group Welcomes Meredith Keyes, CPA, as Chief Financial Officer to Propel Strategic Growth and InnovationVaniam Group, a healthcare communications organization specializing in oncology and rare diseases, has appointed Meredith Keyes, CPA as its new Chief Financial Officer. Keyes brings over 20 years of distinguished financial leadership in the life sciences sector, including prior CFO roles at BioBridges and OPEN Health, and is a recipient of the Triangle Business Journal CFO Award. The appointment aims to scale the company's operational and financial infrastructure as it seeks to strengthen its position as a partner to biotech and pharmaceutical companies advancing transformative therapies.PR NewswireVaniam Group Bolsters Patient Engagement Strategy With Alexandra Dubois as Senior Vice PresidentVaniam Group announced the appointment of Alexandra Dubois as Senior Vice President of Patient Engagement, effective immediately. Dubois brings 25 years of experience, including over a decade dedicated to patient engagement and leadership of The Px Group, which was subsequently acquired by OPEN Health. The appointment is part of Vaniam Group's ongoing strategy to expand its patient engagement capabilities within the biopharma and healthcare communications sector.YahooVaniam Group Bolsters Patient Engagement Strategy With Alexandra Dubois as Senior Vice PresidentVaniam Group appointed Alexandra Dubois as Senior Vice President of Patient Engagement, aiming to integrate patient insights into biopharma strategy. Dubois brings 25 years of experience, including leading The Px Group, and will expand patient engagement capabilities. Further growth and expansion are planned in coming months.PR NewswireVaniam Group™ Introduces Vaniam Intelligence™: Purpose-Built AI, Guided by Human InsightVaniam Group, a Chicago-based medical communications company, announced the launch of Vaniam Intelligence™, an AI-powered platform that combines proprietary artificial intelligence with human oncology expertise to help biopharma companies develop strategies and make decisions. The platform unifies proprietary datasets, strategic insights, and advanced analytics into a single purpose-built system to accelerate decision-making and enhance enterprise connectivity. This launch positions Vaniam Group as a technology-forward partner offering differentiated services in the competitive biopharma communications market.